A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease
Context Non alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD represents a spectrum of liver disease ranging from reversible hepatic steatosis, to non alcoholic steato-hepatitis (NASH) and cirrhosis. The potential role of glucocorticoids (GC) in the...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2012
|
| _version_ | 1797076594152439808 |
|---|---|
| author | Ahmed, A Rabbitt, E Brady, T Brown, C Guest, P Bujalska, I Doig, C Newsome, P Hubscher, S Elias, E Adams, D Tomlinson, J Stewart, P |
| author_facet | Ahmed, A Rabbitt, E Brady, T Brown, C Guest, P Bujalska, I Doig, C Newsome, P Hubscher, S Elias, E Adams, D Tomlinson, J Stewart, P |
| author_sort | Ahmed, A |
| collection | OXFORD |
| description | Context Non alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD represents a spectrum of liver disease ranging from reversible hepatic steatosis, to non alcoholic steato-hepatitis (NASH) and cirrhosis. The potential role of glucocorticoids (GC) in the pathogenesis of NAFLD is highlighted in patients with GC excess, Cushing's syndrome, who develop central adiposity, insulin resistance and in 20% of cases, NAFLD. Although in most cases of NAFLD, circulating cortisol levels are normal, hepatic cortisol availability is controlled by enzymes that regenerate cortisol (F) from inactive cortisone (E) (11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1), or inactivate cortisol through A-ring metabolism (5α- and 5β-reductase, 5αR and 5βR). Objective and Methods In vitro studies defined 11β-HSD1 expression in normal and NASH liver samples. We then characterised hepatic cortisol metabolism in 16 patients with histologically proven NAFLD compared to 32 obese controls using gas chromatographic analysis of 24 hour urine collection and plasma cortisol generation profile following oral cortisone. Results In patients with steatosis 5αR activity was increased, with a decrease in hepatic 11β-HSD1 activity. Total cortisol metabolites were increased in this group consistent with increased GC production rate. In contrast, in patients with NASH, 11β-HSD1 activity was increased both in comparison to patients with steatosis, and controls. Endorsing these findings, 11β-HSD1 mRNA and immunostaining was markedly increased in NASH patients in peri septal hepatocytes and within CD68 positive macrophages within inflamed cirrhotic septa. Conclusion Patients with hepatic steatosis have increased clearance and decreased hepatic regeneration of cortisol and we propose that this may represent a protective mechanism to decrease local GC availability to preserve hepatic metabolic phenotype. With progression to NASH, increased 11β-HSD1 activity and consequent cortisol regeneration may serve to limit hepatic inflammation. |
| first_indexed | 2024-03-07T00:05:54Z |
| format | Journal article |
| id | oxford-uuid:77876b9a-1f63-4c14-9977-a4d369c1098d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:05:54Z |
| publishDate | 2012 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:77876b9a-1f63-4c14-9977-a4d369c1098d2022-03-26T20:24:39ZA switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:77876b9a-1f63-4c14-9977-a4d369c1098dEnglishSymplectic Elements at OxfordPublic Library of Science2012Ahmed, ARabbitt, EBrady, TBrown, CGuest, PBujalska, IDoig, CNewsome, PHubscher, SElias, EAdams, DTomlinson, JStewart, PContext Non alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD represents a spectrum of liver disease ranging from reversible hepatic steatosis, to non alcoholic steato-hepatitis (NASH) and cirrhosis. The potential role of glucocorticoids (GC) in the pathogenesis of NAFLD is highlighted in patients with GC excess, Cushing's syndrome, who develop central adiposity, insulin resistance and in 20% of cases, NAFLD. Although in most cases of NAFLD, circulating cortisol levels are normal, hepatic cortisol availability is controlled by enzymes that regenerate cortisol (F) from inactive cortisone (E) (11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1), or inactivate cortisol through A-ring metabolism (5α- and 5β-reductase, 5αR and 5βR). Objective and Methods In vitro studies defined 11β-HSD1 expression in normal and NASH liver samples. We then characterised hepatic cortisol metabolism in 16 patients with histologically proven NAFLD compared to 32 obese controls using gas chromatographic analysis of 24 hour urine collection and plasma cortisol generation profile following oral cortisone. Results In patients with steatosis 5αR activity was increased, with a decrease in hepatic 11β-HSD1 activity. Total cortisol metabolites were increased in this group consistent with increased GC production rate. In contrast, in patients with NASH, 11β-HSD1 activity was increased both in comparison to patients with steatosis, and controls. Endorsing these findings, 11β-HSD1 mRNA and immunostaining was markedly increased in NASH patients in peri septal hepatocytes and within CD68 positive macrophages within inflamed cirrhotic septa. Conclusion Patients with hepatic steatosis have increased clearance and decreased hepatic regeneration of cortisol and we propose that this may represent a protective mechanism to decrease local GC availability to preserve hepatic metabolic phenotype. With progression to NASH, increased 11β-HSD1 activity and consequent cortisol regeneration may serve to limit hepatic inflammation. |
| spellingShingle | Ahmed, A Rabbitt, E Brady, T Brown, C Guest, P Bujalska, I Doig, C Newsome, P Hubscher, S Elias, E Adams, D Tomlinson, J Stewart, P A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease |
| title | A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease |
| title_full | A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease |
| title_fullStr | A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease |
| title_full_unstemmed | A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease |
| title_short | A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease |
| title_sort | switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease |
| work_keys_str_mv | AT ahmeda aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT rabbitte aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT bradyt aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT brownc aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT guestp aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT bujalskai aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT doigc aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT newsomep aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT hubschers aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT eliase aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT adamsd aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT tomlinsonj aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT stewartp aswitchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT ahmeda switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT rabbitte switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT bradyt switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT brownc switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT guestp switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT bujalskai switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT doigc switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT newsomep switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT hubschers switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT eliase switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT adamsd switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT tomlinsonj switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease AT stewartp switchinhepaticcortisolmetabolismacrossthespectrumofnonalcoholicfattyliverdisease |